Consensus meeting (organization:M.H.and D.Z.) on March 4,2006 concerning the use of rituximab in autoimmune bullous skin disorders; with the kind support of Roche Pharma AG,Grenzach-Wyhlen,Germany.
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases§
Article first published online: 16 JAN 2008
© 2008 The Authors • Journal compilation © Blackwell Verlag, Berlin
JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Volume 6, Issue 5, pages 366–373, May 2008
How to Cite
Hertl, M., Zillikens, D., Borradori, L., Bruckner-Tuderman, L., Burckhard, H., Eming, R., Engert, A., Goebeler, M., Hofmann, S., Hunzelmann, N., Karlhofer, F., Kautz, O., Lippert, U., Niedermeier, A., Nitschke, M., Pfütze, M., Reiser, M., Rose, C., Schmidt, E., Shimanovich, I., Sticherling, M. and Wolff-Franke, S. (2008), Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 6: 366–373. doi: 10.1111/j.1610-0387.2007.06602.x
- Issue published online: 16 JAN 2008
- Article first published online: 16 JAN 2008
- Submitted: 25. 6. 2007 | Accepted: 29. 9. 2007
- B lymphocyte;
- Immune suppression;
- Bullous skin diseases
Autoimmune bullous skin disorders are induced by autoantibodies against distinct adhesion complexes of the epidermal and dermal-epidermal junction. Since most of these disorders are characterized by a severe, potentially lethal course,they require long-term immunosuppressive treatment to reduce the de novo synthesis of pathogenic autoantibodies by B lymphocytes. Rituximab, a chimeric monoclonal antibody against CD20 on B lymphocytes, has shown promise in several case reports or cohort studies in the treatment of paraneo-plastic pemphigus,refractory cases of pemphigus vulgaris and foliaceus and in other autoimmune bullous disorders.Treatment with rituximab leads to depletion of pathogenic B-cells which may last up to 12 months resulting in a reduction of plasma cells secreting pathogenic autoantibodies.Rituximab is usually administered in an adjuvant setting at a dose of 375 mg/m2 i.v.in weekly intervals for four consecutive weeks in addition to the standard immunosuppressive treatment.The present consensus statement of German-speaking derma-tologists,rheumatologists and oncologists summarizes and evaluates the current evidence for the use and mode of application of rituximab in autoimmune bullous skin disorders.